

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/039619 A1

(51) International Patent Classification⁷: **A61K 38/17**,
31/5575, A61P 27/02 // (A61K 31/5575, 38:17)

(74) Agents: **JOHNSON, Brent, A. et al.**; Allergan, Inc., 2525
Dupont Drive, Irvine, CA 92612 (US).

(21) International Application Number:
PCT/US2004/027777

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(22) International Filing Date: 25 August 2004 (25.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/508,445 3 October 2003 (03.10.2003) US

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ALLER-
GAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, CA
92612 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BAKHIT, Peter**,
G. [US/US]; 21661 Brookhurst #144, Huntington Beach,
CA 92646 (US). **GRAHAM, Richard** [US/US]; 5066
Balsawood, Irvine, CA 92612 (US). **OLEJNIK, Orest**
[US/US]; 5 Addington Place, Coto De Caza, CA 92679
(US).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 2005/039619 A1

(54) Title: COMPOSITIONS AND METHODS COMPRISING PROSTAGLANDIN-RELATED COMPOUNDS AND TREFOIL
FACTOR FAMILY PEPTIDES FOR THE TREATMENT OF GLAUCOMA WITH REDUCED HYPEREMIA

(57) Abstract: Compositions, methods, and pharmaceutical products related to prostaglandin-related compounds and trefoil factor
family peptides are disclosed herein. Of particular interest are compositions and methods useful for the treatment of glaucoma with
a reduced occurrence of hyperemia.

**COMPOSITIONS AND METHODS COMPRISING PROSTAGLANDIN-
RELATED COMPOUNDS AND TREFOIL FACTOR FAMILY PEPTIDES
FOR THE TREATMENT OF GLAUCOMA WITH REDUCED
HYPEREMIA**

5

Field of the Invention

The present invention relates to pharmaceutical compositions comprising prostaglandin-related compounds and trefoil factor family peptides.

10

Background of the Invention

Description of Related Art

15 Active drugs often have undesirable side effects at their therapeutically effective concentrations. This is particularly problematic for topical use in sensitive areas such as the eyes, where irritation is very difficult to avoid even for relatively mild drugs. As a result, formulating topical ophthalmic drugs is a particularly challenging problem. This is unfortunate because topical ophthalmic
20 use of drugs has been found to be very useful in managing many conditions affecting the eye such as dry eye, infection, inflammation, allergy, and glaucoma. Glaucoma is a particularly devastating disease of the eye characterized by increased intraocular pressure, which is often treated by topical ophthalmic application of a drug. Glaucoma occurs in about 2% of all persons over the age
25 of 40 and may be asymptotic for years before progressing to rapid loss of vision. In cases where surgery is not indicated, many drugs have been found to be useful in treating glaucoma by topical application including β -adrenoreceptor antagonists and α_2 -adrenoreceptor agonists. Recently, prostaglandins have been shown to be particularly useful in the topical treatment of glaucoma.

30 Whereas prostaglandins appear to be devoid of significant intraocular side effects, ocular surface (conjunctival) hyperemia, foreign-body sensation, and itching (pruritus) have been consistently associated with the topical ocular use of such compounds, in particular $\text{PGF}_2\alpha$ and its prodrugs, e.g., its 1-isopropyl ester,

in humans. The clinical potentials of prostaglandins in the management of conditions associated with increased ocular pressure, e.g. glaucoma are greatly limited by these side effects.


US Patent No. 5,688, 819, commonly assigned to Allergan, Inc., and
5 incorporated herein by reference discloses compounds known as prostamides. Prostamides are distinguished from prostaglandins in that the oxygen which is bonded to carbonyl group is replaced by a nitrogen bearing substituent. Those skilled in the art will readily recognize that this replacement significantly alters several electronic and steric properties of an important structural feature in the
10 biological molecule. Significantly, it is commonly believed in the art that resonance between the nitrogen lone pair and the carbonyl π -bond is significantly greater than resonance between the carbonyl group and an oxygen lone pair in a carboxylic ester or a carboxylic acid. This belief is supported by the well established experimental observation that the nitrogen atom in an
15 amide is planar, as opposed to the pyramidal geometry of an amine. Thus, the commonly accepted belief in the art is that the nitrogen atom of an amine is sp^3 hybridized, while nitrogen atom of an amide is sp^2 hybridized, with the bonded electrons occupying the sp^2 hybrid orbitals and the nonbonded electron pair occupying a p orbital to allow for conjugation with the carbonyl π system. By
20 contrast, the hybridization, bonding, and geometry of the electrons of the oxygen atom in water and alcohols are very similar to those of carboxylic acids or carboxylic esters.

The increased resonance between the nitrogen and the carbonyl group in the amide confers several unique properties to the molecule. First, it is well
25 known in the art that hydrolysis of amides is at least two orders of magnitude slower than the hydrolysis of esters (see, for example, Francis A. Carey, Organic Chemistry, New York: McGraw-Hill Book Company, 1987, p. 779). Thus, hydrolysis of amides in vivo is slowed to such an extent that a prostamide cannot be considered to be a prodrug of a prostaglandin. Second, the increased
30 resonance significantly increases the barrier to rotation about the nitrogen-carbonyl sigma bond relative to the analogous rotational barrier associated with

esters and carboxylic acids. Thus, a prostamide has a sterically significant, stable, rigid group replacing the oxygen atom of the prostaglandin. This significant steric difference will have a significant effect in binding to a number of receptor sites since geometry is important for many receptor sites. Since the
5 carboxylic acid group of a prostaglandin is a polar, ionizable, group, with four potential hydrogen bond receiving electron pairs, and in the case of the protonated acid, one potential hydrogen bond donor, it is reasonable for a person of ordinary skill in the art to believe that this functional group will be important to the binding of the molecule to a number of receptors. It follows
10 that changing the resonance properties, the hybridization of the bonding and nonbonding electrons, the geometry of the nitrogen atom, the number of available hydrogen bonding sites, and the electronegativity of the of the nitrogen relative to oxygen, will confer significantly different biological properties to prostamides relative to prostaglandins.

15 Recently, it is becoming more commonly accepted in the art that amides have distinct properties over carboxylic acids. For example, it has been shown that anandamide, a common amide of arachidonic acid, has significant biological activity that arachidonic acid does not. Other work has also been done to show that amides have distinct activity as compared to carboxylic acid,
20 which has caused some in the field to classify fatty acid amides as "a new family of biologically active lipids" (Bezuglov, et. al., "Synthesis and Biological Evaluation of Novel Amides of Polyunsaturated Fatty Acids with Dopamine", *Bioorganic & Medicinal Chemistry Letters* 11 (2001), 447-449).

It has been shown that prostamides have pronounced effects on smooth
25 muscle and are potent ocular hypotensive agents. Additionally, prostamides cause significantly lower ocular surface hyperemia than prostaglandins. One prostamide exemplary of the these effects is bimatoprost, which is marketed by Allergan, Inc. under the trade name Lumigan®, which has the structure shown in Formula I below.



Formula I

However, although bimatoprost is associated with significantly less hyperemia and other irritating side effects compared to certain prostaglandins, further
5 improvement is still highly desirable.

Trefoil peptides, or trefoil factor family (TFF) peptides are a class of peptides which comprise a common structural motif, known as the trefoil domain, as part of their structure. The trefoil motif comprises about 20 to about 60 amino acid residues (usually about 40) containing six cysteine residues. The
10 six cysteine residues form three disulfide bridges that complete three loops in the peptide chain so that the roughly 40 residues have a clover-like shape, known as the trefoil domain. TFF-peptides can have one or two trefoil domains per molecule, and may comprise additional amino acid residues which are not part of the trefoil domain. To date, three types of TFF-peptides have been
15 isolated from humans-TFF1 (also known as pS2), TFF2 (also known as SP), and TFF3 (also known as ITF). TFF1 and TFF3 peptides each contain one trefoil domain, while TFF2 peptides contain two trefoil domains. TFF1 and TFF2 peptides are both produced by mucus-producing cells of stomach, while TFF3 peptides are produced by goblet cells of small and large intestine.

20 All three forms of TFF-peptides are known to be produced in epithelial cells around areas of damage to mucus membrane, suggesting that trefoils have a role in healing injury, particularly to epithelial cells. It is believed that TFF-peptides assist healing by both stabilizing mucus membrane at the injury site and by stimulating repair. It has been shown that TFF-peptides noncovalently

link mucin, thus influencing the rheology (e.g. increases viscosity) of mucus gels. [Hauser F, Poulsom R, Chinery R, *et al*, *Proc Natl Acad Sci USA*, 1993, vol. 90, pp. 6961-6965; and Babyatsky MW, deBeaumont M, Thim L, Podolky DK, *Gastroenterology*, 1996, vol. 110, pp. 489-497]. TFF-peptides also appear
5 to be responsible for promoting the migration of epithelial cells to the site of injury, thus stimulating repair. [Göke M, *et al*, *Experimental Cell Research*, 2001, vol 264, pp. 337-344; and Playford RJ, *Journal of the Royal College of Physicians of London*, vol 31, pp. 37-40]

Although there is still a great deal unknown about the role of TFF
10 peptides on the ocular surface, in the lacrimal gland, in the efferent passages, and in surrounding tissue, it is believed that TFF-peptides may be present during healing and other related processes in the eye. Biosynthesis and storage TFF1 and TFF3 peptides, but not TFF2, is known to occur in the human conjunctival epithelium [Langer G, *et al*, *Invest Ophthalmol Vis Sci*, 1999, vol.
15 40, pp. 2220-2224], and in vitro studies have shown that TFF2 and TFF3 peptides promote the migration of wounded corneal epithelial cells from rabbits [Göke M, *et al*, *Experimental Cell Research*, 2001, vol 264, pp. 337-344]. However, to the best of our knowledge, no direct relationship has been unambiguously established between TFF-peptides and any pathological
20 condition affecting the eye.

Summary Of The Invention


Disclosed herein are dosage forms and methods which comprise a prostaglandin or a prostamide and a trefoil factor family peptide.

Detailed Description of The Invention

Disclosed herein are dosage forms which comprise a prostaglandin or a prostamide and a trefoil factor family peptide. Also disclosed are methods of treating ocular or conjunctival hyperemia in a person comprising administering topically to an eye of said person a therapeutically effective amount of a trefoil
30 factor family peptide, wherein said person is being treated for glaucoma with a prostaglandin-related compound.

In relation to the methods disclosed herein, the individual properties of the prostaglandin-related compound and the trefoil factor family peptide may be considerations in determining how the two are administered. In certain embodiments the prostaglandin-related compound and trefoil factor family are administered in a single composition. In other embodiments, the prostaglandin-related compound and the trefoil factor family peptide are administered separately. In other embodiments, the prostaglandin-related compound and the trefoil factor family peptide are administered simultaneously. In other embodiments, the prostaglandin-related compound and the trefoil factor family peptide are administered at substantially different times. In other embodiments, the prostaglandin-related compound and the trefoil factor family peptide are administered with equal frequency. In other embodiments, the prostaglandin-related compound is administered more frequently than the trefoil factor family peptide. In other embodiments, the prostaglandin-related compound is administered less frequently than the trefoil factor family peptide.

A "prostaglandin-related compound" is broadly defined as any compound related to a prostaglandin by being a natural prostaglandin, a prostaglandin analog, a prostaglandin receptor agonist, a prostamide, or a pharmaceutically acceptable salt, or a prodrug of any of the previous classes. Natural prostaglandins can be described as derivatives of prostanoid acid which have the following structural formula:



In relation to the structure above and prostaglandin-related compounds, term "α chain" refers to the top chain which is formed by the carbon atoms

referred to as 1-7 in the structure above. The term " ω chain" refers to the bottom chain which is formed by the carbon atoms referred to as 13-20 in the structure above. The ring formed by the carbon atoms referred to as 8-12 will be referred to as the "cyclopentyl ring" herein for convenience. Natural
5 prostaglandins are characterized by the presence of functional groups or double bonds on their cyclopentyl ring, and by the presence or absence of a cis double bond between carbons 5 and 6, and by the presence or absence of a trans double bond between carbons 13 and 14. Such nomenclature is well known in the art. However, while not desiring to limit the scope of the invention in any way,
10 some important groups of natural prostaglandin compounds are prostaglandin E, prostaglandin F, and prostaglandin D. Prostaglandin E is characterized by a carbonyl group at carbon 9 and a hydroxyl group at carbon 11 which is in the alpha configuration. One prostaglandin E which is of interest herein is prostaglandin E₁, which has a single covalent bond between carbons 5 and 6 and
15 a double covalent bond between carbons 13 and 14. Another prostaglandin E of interest herein is prostaglandin E₂, which has a double covalent bond between carbons 5 and 6 and a double covalent bond between carbons 13 and 14. Thus, the subscript designates the number of carbon-carbon double bonds found in the basic prostaglandin structure.

20 The compounds known collectively as prostaglandin F are characterized by the common features that both carbons 9 and 11 have hydroxyl groups attached. Similar to prostaglandin E the OH is in the α -configuration for carbon 11, but the configuration of the OH at carbon 9 is designated by a subscript. Thus, prostaglandin F_{2 α} , which is of particular interest herein, is a prostaglandin
25 F which has the OH of carbon 9 in the α -configuration, and similar to prostaglandin E₂, prostaglandin F_{2 α} has two double covalent carbon-carbon bonds between carbons 5 and 6 and carbons 13 and 14.

The compounds known collectively as prostaglandin D are characterized by the common features that carbon 9 is CHOH, where the OH is in the α -
30 configuration, and carbon 11 is C=O. Similar to the previous examples, one

prostaglandin D of interest herein is designated prostaglandin D₂, which indicates that the compound has two double covalent carbon-carbon bonds between carbons 5 and 6 and carbons 13 and 14.

A "prostaglandin analog" as used herein refers to a compound having
5 certain structural similarities to the natural prostaglandins. An analog has all of the features of a natural prostaglandin related to the cyclopentyl ring, including stereochemistry, the α -hydroxyl group at C15, and the presence or absence of double bonds at carbons 5, 6, 13 and 14, or reasonable equivalents of those features. A reasonable equivalent to a feature is a feature that a person of
10 ordinary skill in the art would reasonably consider as having a similar purpose, but might enhance the properties of the compound. While not intending to limit the scope of the invention in any way, in general, an atom or functional group which is isovalent or isoelectronic with the atom or functional group it is replacing would be a reasonable equivalent. Thus, for example, an α -CHSH
15 group is a reasonable equivalent for an α -CHOH group, and a C=S group is a reasonable equivalent for a C=O group. Another type of reasonable equivalent has different electronic properties but similar steric properties to the group it is replacing. Thus, F is a reasonable equivalent for H and OCH₃ is a reasonable equivalent for OH.

20 Beyond the similarities for the cyclopentyl ring and the double bonds indicated, a prostaglandin analog will have an α -chain and an ω -chain which are attached to adjacent atoms on the cyclopentyl ring. The meanings of the cyclopentyl ring and the α and ω chains for prostaglandin analogs are broader than those of the natural prostaglandins. For a prostaglandin analog, the
25 "cyclopentyl ring" is a five-membered ring consisting of three or more carbon atoms, the " α -chain" has between 4 and 12 carbon atoms and the " ω -chain" has between 4 and 20 carbon atoms. Either chain may comprise double or triple covalent bonds, aromatic or aliphatic rings, and heteroatoms such as S, O, N, and halogens. The only stereochemical requirements of prostaglandin analogs
30 are the same as those of the natural prostaglandins they are associated with.

Thus, for a prostaglandin E analog, carbon 9 and carbon 11 should be CHOH with the OH in the α -configuration, and the α - and ω -chains should have the α and β configurations respectively with relation to the connection to the cyclopentyl ring. The table below lists features which would be present in
5 analogs of several types of natural prostaglandins. Alternatively, a reasonable equivalent for each feature might be present in the given prostaglandin analog.

Prostaglandin Analog	C9	C11	C15	C5-C6	C13-C14
E	C=O	CH(OH) α conf	CH(OH) α conf	NA	NA
E ₁	C=O	CH(OH) α conf	CH(OH) α conf	single bond	trans double bond
E ₂	C=O	CH(OH) α conf	CH(OH) α conf	cis double bond	trans double bond
F	CH(OH)	CH(OH) α conf	CH(OH) α conf	NA	NA
F _{2a}	CH(OH) α conf	CH(OH) α conf	CH(OH) α conf	cis double bond	trans double bond
D	CH(OH) α conf	C=O	CH(OH) α conf	NA	NA
D ₂	CH(OH) α conf	C=O	CH(OH) α conf	cis double bond	trans double bond

NA means there is no requirement.

“A prostaglandin receptor agonist” refers to a compound which binds to and activates one of the prostaglandin receptors at a concentration of less than 10^4 nanomolar according to the Radioligand Binding and the FLIPR™ assay described hereafter. Of particular interest herein are compounds having agonist activity at an FP receptor, an EP₂ receptor, an EP₄ receptor, and/or a DP receptor.

10 Radioligand Binding

Cells Stably Expressing EP₁, EP₂, EP₄ and FP Receptors

HEK-293 cells stably expressing the human or feline FP receptor, or EP₁, EP₂, or EP₄ receptors were washed with TME buffer, scraped from the bottom of the flasks, and homogenized for 30 sec using a Brinkman PT 10/35 polytron. TME buffer was added to achieve a final 40 ml volume in the centrifuge tubes (the composition of TME is 100 mM TRIS base, 20 mM MgCl₂, 2M EDTA; 10N HCl is added to achieve a pH of 7.4).

The cell homogenate was centrifuged at 19000 r.p.m. for 20 min at 4° C using a Beckman Ti-60 rotor. The resultant pellet was resuspended in TME buffer to give a final 1 mg/ml protein concentration, as determined by Biorad assay. Radioligand binding competition assays vs. [³H]-17 β -phenyl PGF_{2 α} (5 nM) were performed in a 100 μ l volume for 60 min. Binding reactions were

started by adding plasma membrane fraction. The reaction was terminated by the addition of 4 ml ice-cold TRIS-HCl buffer and rapid filtration through glass fiber GF/B filters using a Brandel cell harvester. The filters were washed 3 times with ice-cold buffer and oven dried for one hour.

- 5 [^3H] PGE₂ (specific activity 180 Ci mmol) was used as the radioligand for EP receptors. [^3H] 17-phenyl PGF_{2 α} was employed for FP receptor binding studies. Binding studies employing EP₁, EP₂, EP₄ and FP receptors were performed in duplicate in at least three separate experiments. A 200 μl assay volume was used. Incubations were for 60 min at 25°C and were terminated by
- 10 the addition of 4 ml of ice-cold 50 mM TRIS-HCl, followed by rapid filtration through Whatman GF/B filters and three additional 4 ml washes in a cell harvester (Brandel). Competition studies were performed using a final concentration of 5 nM [^3H]-PGE₂, or 5 nM [^3H] 17-phenyl PGF_{2 α} and non-specific binding determined with 10⁻⁵M of unlabeled PGE₂, or 17-phenyl
- 15 PGF_{2 α} , according to receptor subtype studied.

METHODS FOR FLIPR™ STUDIES

(a) CELL CULTURE

- HEK-293(EBNA) cells, stably expressing one type or subtype of recombinant human prostaglandin receptors (prostaglandin receptors expressed:
- 20 hDP/Gqs5; hEP₁; hEP₂/Gqs5; hEP_{3A}/Gqi5; hEP₄/Gqs5; hFP; hIP; hTP), were cultured in 100 mm culture dishes in high-glucose DMEM medium containing 10% fetal bovine serum, 2 mM l-glutamine, 250 $\mu\text{g}/\text{ml}$ geneticin (G418) and 200 $\mu\text{g}/\text{ml}$ hygromycin B as selection markers, and 100 units/ml penicillin G, 100 $\mu\text{g}/\text{ml}$ streptomycin and 0.25 $\mu\text{g}/\text{ml}$ amphotericin B.

25 (b) CALCIUM SIGNAL STUDIES ON THE FLIPR™

- Cells were seeded at a density of 5x10⁴ cells per well in Biocoat® Poly-D-lysine-coated black-wall, clear-bottom 96-well plates (Becton-Dickinson) and allowed to attach overnight in an incubator at 37 °C. Cells were then washed two times with HBSS-HEPES buffer (Hanks Balanced Salt Solution
- 30 without bicarbonate and phenol red, 20 mM HEPES, pH 7.4) using a Denley

Cellwash plate washer (Labsystems). After 45 minutes of dye-loading in the dark, using the calcium-sensitive dye Fluo-4 AM at a final concentration of 2 μ M, plates were washed four times with HBSS-HEPES buffer to remove excess dye leaving 100 μ l in each well. Plates were re-equilibrated to 37 °C for a few
5 minutes.

Cells were excited with an Argon laser at 488 nm, and emission was measured through a 510-570 nm bandwidth emission filter (FLIPR™, Molecular Devices, Sunnyvale, CA). Drug solution was added in a 50 μ l volume to each well to give the desired final concentration. The peak increase in
10 fluorescence intensity was recorded for each well. On each plate, four wells each served as negative (HBSS-HEPES buffer) and positive controls (standard agonists: BW245C (hDP); PGE₂ (hEP₁; hEP₂/Gqs5; hEP_{3A}/Gqi5; hEP₄/Gqs5); PGF_{2 α} (hFP); carbacyclin (hIP); U-46619 (hTP), depending on receptor). The peak fluorescence change in each drug-containing well was then expressed
15 relative to the controls.

Compounds were tested in a high-throughput (HTS) or concentration-response (CoRe) format. In the HTS format, forty-four compounds per plate were examined in duplicates at a concentration of 10⁻⁵ M. To generate concentration-response curves, four compounds per plate were tested in duplicates in a
20 concentration range between 10⁻⁵ and 10⁻¹¹ M. The duplicate values were averaged. In either, HTS or CoRe format each compound was tested on at least 3 separate plates using cells from different passages to give an n \geq 3.

Prostamides are also considered to be "prostaglandin-related" compounds. For the purposes of this disclosure, the term amide has the
25 broadest meaning generally understood by organic chemists. Prostamides are prepared by methods generally known in the art, and also by the methods described in US Patent No. 5,688, 819, incorporated herein by reference. One important embodiment relates to the use of bimatoprost in the compositions and methods disclosed herein. Bimatoprost is marketed under the tradename
30 Lumigan® by Allergan, Inc.

The term "prodrug" used herein has the meaning normally understood in the art. That is, the prodrug is a compound which readily decomposes in vivo to form a natural prostaglandin, a prostaglandin analog, a prostamide or a prostaglandin receptor agonist. While not intending to limit the scope of the invention in any way, one common type of prodrug is an ester which hydrolyzes to yield an active compound with a hydroxide functional group.

The term "salt" has the meaning normally understood by those of ordinary skill in the art. A "pharmaceutically acceptable salt" is any salt that retains the activity of the parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered.

Pharmaceutically acceptable salts of acidic functional groups may be derived from organic or inorganic bases. The salt may be a mono or polyvalent ion. Of particular interest are the inorganic ions, lithium, sodium, potassium, calcium, and magnesium. Organic salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine and similar molecules. Hydrochloric acid or some other pharmaceutically acceptable acid may form a salt with a compound that includes a basic group, such as an amine or a pyridine ring.

Certain terminology is used to refer to particular prostaglandin-related classes of compounds. A compound which is referred to as "prostaglandin F-related" is a natural prostaglandin F, a prostaglandin F analog, a prostaglandin FP receptor agonist, or a prostamide having the characteristic features of prostaglandin F analog as described previously, or a salt or a prodrug of any of the previous classes of compounds. Similar terminology can be used to identify other prostaglandin compounds related to different classes of prostaglandins such as prostaglandin E ("prostaglandin E-related") or prostaglandin D ("prostaglandin D-related").

The quantity or concentration of a prostaglandin-related compound to be used in the compositions and methods disclosed herein can be determined by

one of ordinary skill in the art without undue experimentation. In one embodiment, the concentration of the prostaglandin-related compound in the dosage form in which it is administered is from 0.001% to 0.1%. In another embodiment, the concentration of the prostaglandin-related compound in the dosage form in which it is administered is about 0.03%.

The term trefoil factor family (TFF) peptide as used herein refers to any peptide, whether natural or synthetic, which comprises the trefoil motif described previously herein. That is, the TFF-peptide comprises a residue comprising from 20 to about 60 amino acids, including six cysteine residues. The cysteine residues form disulfide bonds which cause the peptide residue to have a clover-like shape comprising three loops. The methods of preparing of TFF-peptides, such as recombinant expression of peptides and synthetic peptide synthesis, are well known in the art. For example, methods of preparing TFF-peptides are included in the following references: US Pat. No. 6,525,018; Allen, et. al., *J Clin Gastroenterol* 1998; 10 (Suppl 1): S93-S98; Ligumsky, et. al., *Isr J Med Sci* 1986; 22:801-806; Dignass, et. al., *J. Clin. Invest.*, 94, 376-383; Babyatsky, et. al., *Gastroenterology*, 110, 489-497; Hauser, et. al., *Proc. Natl. Acad. Sci. USA*, vol. 90, pp. 6961-6965, August 1993; WO 02102403; and WO02085402, incorporated herein by reference. In one embodiment the trefoil factor family peptide is TFF1, TFF2, or TFF3. In another embodiment the trefoil factor family peptide is TFF1 or TFF3.

The concentration or amount of the trefoil factor family peptide used in the methods and compositions disclosed herein can readily be determined by one of ordinary skill in the art without undue experimentation. In one embodiment, the concentration of the trefoil factor family peptide is from 0.001% to 1%. In another embodiment, the concentration of the trefoil factor family peptide is from 0.01% to 0.5%. In another embodiment, the concentration of the trefoil factor family peptide is from 0.1% to 0.2%. In another embodiment, the concentration of the trefoil factor family peptide is about 0.15%.

A mucoadhesive is used in certain of the compositions and methods disclosed herein. With respect to this invention, the term "mucoadhesive" means a natural or synthetic component, including macromolecules, polymers, and oligomers, or mixtures thereof, that can adhere to a subject's mucous

5 membrane. Adhesion of mucoadhesives to the mucous membrane occurs primarily through noncovalent interactions, such as hydrogen bonding and Van der Waal forces (Tabor et al., 1977 J. Colloid Interface Sci. 58:2 and Good 1977 J. Colloid Interface Sci. 59:398). Examples of mucoadhesives for use in the embodiments disclosed herein include, but are not limited to, Carbopol®,

10 pectin, alginic acid, alginate, chitosan, hyaluronic acid, polysorbates, such as polysorbate-20, -21, -40, -60, -61, -65, -80, -81, -85; poly(ethyleneglycol), such as PEG-7, -14, -16, -18, -55, -90, -100, -135, -180, -4, -240, -6, -8, -9, -10, -12, -20, or -32; oligosaccharides and polysaccharides, such as Tamarind seed polysaccharide, gellan, carrageenan, xanthan gum, gum Arabic, and dextran;

15 cellulose esters and cellulose ethers; modified cellulose polymers, such as carboxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl ethylcellulose; polyether polymers and oligomers, such as polyoxyethylene; condensation products of poly(ethyleneoxide) with various reactive hydrogen containing compounds having long hydrophobic chains (e.g.

20 aliphatic chains of about 12 to 20 carbon atoms), for example, condensation products of poly(ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols; polyether compounds, such as poly(methyl vinyl ether), polyoxypropylene of less than 10 repeating units; polyether compounds, such as block copolymers of ethylene oxide and propylene oxide; mixtures of block

25 copolymers of ethylene oxide and propylene oxide with other excipients, for example poly(vinyl alcohol); polyacrylamide; hydrolyzed polyacrylamide; poly(vinyl pyrrolidone); poly(methacrylic acid); poly(acrylic acid) or crosslinked polyacrylic acid, such as Carbomer®, i.e., a homopolymer of acrylic acid crosslinked with either an allyl ether of pentaerythritol, an allyl

30 ether of sucrose, or an allyl ether of propylene. In certain embodiments the mucoadhesive is a polysaccharide. One polysaccharide which is particularly

useful as a mucoadhesive in the embodiments disclosed herein is Tamarind seed polysaccharide, which is a galactoxyloglucan that is extracted from the seed kernel of *Tamarindus Indica*, and can be purchased from TCI America of Portland, OR

5 In certain embodiments a buffer is included to maintain the pH from about 6 to about 8. In particular cases, it is desirable to maintain the pH about 7. Buffers used are those known to those skilled in the art, and, while not intending to be limiting, some examples are acetate, borate, carbonate, citrate, and phosphate buffers. Preferably, the buffer comprises borate. An effective amount
10 of buffer necessary for the purposes of this invention can be readily determined by a person skilled in the art without undue experimentation. In certain embodiments where the buffer comprises borate, the concentration of the borate buffer is about 0.6%.

 In any of the compositions described herein, a tonicity agent may be used.
15 Tonicity agents are used in ophthalmic compositions to adjust the concentration of dissolved material to the desired isotonic range. Tonicity agents are known to those skilled in the ophthalmic art, and, while not intending to be limiting, some examples include glycerin, mannitol, sorbitol, sodium chloride, and other electrolytes. On particularly useful tonicity agent is sodium chloride.

20 In any of the compositions are described herein, a preservative may be used, particularly when the composition is intended for multiple use. There may also be reasons to use a preservative in single use compositions depending on the individual circumstances. The term preservative has the meaning commonly understood in the ophthalmic art. Preservatives are used to prevent bacterial
25 contamination in multiple-use ophthalmic preparations, and, while not intending to be limiting, examples include benzalkonium chloride, stabilized oxychloro complexes (otherwise known as Purite®), phenylmercuric acetate, chlorobutanol, benzyl alcohol, parabens, and thimerosal. One particularly useful preservative is benzalkonium chloride (BAK).

30 Under certain circumstances, a surfactant might be used in any of the compositions related to this invention which are described herein. The term

surfactant used herein has the meaning commonly understood in the art.

Surfactants are used to help solubilize the therapeutically active agent or other insoluble components of the composition, and may serve other purposes as well.

Anionic, cationic, amphoteric, zwitterionic, and nonionic surfactants may all be
5 used in this invention. Nonionic surfactants, such as polysorbates, poloxamers, alcohol ethoxylates, ethylene glycol-propylene glycol block copolymers, fatty acid amides, alkylphenol ethoxylates, or phospholipids, are particularly useful for the compositions and methods disclosed herein.

Another type of compound that might be used in any composition
10 described herein is a chelating agent. The term chelating agent refers to a compound that is capable of complexing a metal, as understood by those of ordinary skill in the chemical art. Chelating agents are used in ophthalmic compositions to enhance preservative effectiveness. While not intending to be limiting, some useful chelating agents are edetate salts, like edetate disodium,
15 edetate calcium disodium, edetate sodium, edetate trisodium, and edetate dipotassium.

One particularly useful embodiment comprises a prostaglandin-related compound at a concentration from 0.001% to 0.1%, a trefoil factor family peptide, tamarind seed polysaccharide, about 0.5% sodium chloride, about
20 0.005% benzalkonium chloride, and about 0.6% of a borate buffer wherein the pH of the composition is adjusted to from about 6 to about 8. In one composition, the prostaglandin-related compound is bimatoprost, which is present at a concentration of 0.03%. In another composition, the prostaglandin-related compound is latanoprost, which is present at a concentration of 0.005%.
25 In another composition, the prostaglandin-related compound is travoprost, which is present at a concentration of 0.004%. In another composition, the prostaglandin-related compound is unoprostone isopropyl, which is present at a concentration of 0.15%.

Another embodiment relates to a pharmaceutical product comprising
30 a composition comprising a therapeutically effective amount of a prostaglandin F-related compound and a therapeutically effective concentration of a trefoil

factor family peptide, and a package suitable for ophthalmic use from which said composition is dispensed, wherein the use of the composition for the prevention or treatment of glaucoma is indicated thereon.

The best mode of making and using the present invention are described in the following examples. These examples are given only to provide direction and guidance in how to make and use the invention, and are not intended to limit the scope of the invention in any way.

Example 1

Compositions related to this invention are prepared by the following procedure. Unless otherwise indicated, all procedural steps are carried out at room temperature.

Part I

Tamarind seed polysaccharide (TSP) is added to purified water at the concentration indicated in the Table 1, and the solution is brought to a boil and maintained at a gentle boil for about 30 minutes. The solution is then allowed to cool to room temperature, and water is added to compensate for evaporative loss during boiling. The solution is then filtered through a 20 micron clarity filter followed by a 0.45 micron sterilizing filter.

20

Part II

Each component listed in Table 1 is added in amount needed to provide the indicated concentration to a fixed volume of the solution from part I, in the following order: TFF 1, boric acid, sodium borate decahydrate, sodium chloride, and BAK. After the addition of each component, the mixture is stirred until the solute is completely dissolved before the next component is added. When all of the components of the formulation have been added and dissolved, the pH is then adjusted to 7.0 with NaOH or HCl. The solution is then sterile filtered.

25

30

Table 1

Component	Function	% (w/v)
Bimatoprost	Prostamide	0.03
TFF 1	TFF-peptide	0.15
Tamarind Seed Polysaccharide (TSP)	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Preservative	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

Example 2

A formulation having the composition of Table 2 is prepared according to an analogous procedure to that of Example 1. Latanoprost is well known in the art, and can be prepared by procedures described in US Patent No. 6,429,226, incorporated herein by reference.

Table 2

Component	Function	% (w/v)
Latanoprost	Prostaglandin	0.005
TFF 1	TFF-peptide	0.15
Tamarind Seed Polysaccharide (TSP)	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Preservative	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

Example 3

A formulation having the composition of Table 3 is prepared according to an analogous procedure to that of Example 1.

Table 3

Component	Function	% (w/v)
Bimatoprost	Prostamide	0.03
TFF 1	TFF-peptide	0.15
Sodium Carboxymethylcellulose	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Preservative	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

5

Example 4

A formulation having the composition of Table 4 is prepared according to an analogous procedure to that of Example 1.

10 Table 4

Component	Function	% (w/v)
Bimatoprost	Prostamide	0.03
TFF 3	TFF-peptide	0.15
Hydroxypropylmethylcellulose	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Preservative	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

Example 5

A formulation having the composition of Table 5 is prepared according to an analogous procedure to that of Example 1.

5

Table 5

Component	Function	% (w/v)
Bimatoprost	Prostamide	0.03
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Preservative	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

Example 6

A formulation having the composition of Table 6 is prepared according to an analogous procedure to that of Example 1.

10

Table 6

Component	Function	% (w/v)
Travoprost	Prostaglandin	0.004
TFF 1	TFF-peptide	0.15
Sodium Carboxymethylcellulose	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Preservative	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

Example 7

A formulation having the composition of Table 7 is prepared according to an analogous procedure to that of Example 1.

5 Table 7

Component	Function	% (w/v)
Unoprostone isopropyl	Prostamide	0.15%
TFF 3	TFF-peptide	0.15
Hydroxypropylmethylcellulose	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Preservative	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

Example 8

A drop of a composition prepared according to one of Examples 1 and 3-5 is added at least once a day to several patients suffering from glaucoma. Reduction in intraocular pressure is observed for all patients, but with reduced hyperemia observed in the patients receiving the compositions of Examples 1, 3 and 4, which have a trefoil factor family peptide, relative to the patients receiving the composition of Example 5.

15

20

CLAIMS

What is claimed is:

- 5 1. A dosage form comprising a prostaglandin or a prostamide and a trefoil factor family peptide.
2. The dosage form of claim 1 wherein the concentration of the prostaglandin or prostamide is from 0.001% to 0.1%.
3. The dosage form of claim 1 wherein the concentration of the trefoil
10 factor family peptide is from 0.001% to 1%.
4. The dosage form of claim 1 wherein the concentration of the trefoil factor family peptide is from 0.01% to 0.5%.
5. The dosage form of claim 1 wherein the concentration of the trefoil factor family peptide is from 0.1% to 0.2%.
- 15 6. The dosage form of claim 1 wherein the concentration of the trefoil factor family peptide is about 0.15%.
7. The dosage form of claim 1 which further comprises a mucoadhesive.
8. The dosage form of claim 1 which further comprises a polysaccharide.
9. The dosage form of claim 1 which further comprises Tamarind seed
20 polysaccharide.
10. The dosage form of claim 1 wherein the trefoil family factor peptide is TFF3.
11. The dosage form of claim 1 wherein the trefoil family factor peptide is TFF1.
- 25 12. The dosage form of claim 1 wherein said dosage form comprises bimatoprost.
13. The dosage form of claim 9 which comprises bimatoprost.
14. A method of treating ocular or conjunctival hyperemia in a person comprising administering topically to an eye of said person a therapeutically
30 effective amount of a trefoil factor family peptide, wherein said person is being

treated for glaucoma or elevated intraocular pressure with a prostaglandin-related compound.

15. The method of claim 14 wherein the trefoil factor family peptide and the prostaglandin-related compound are administered in a single composition.

5 16. The method of claim 14 wherein the trefoil factor family peptide and the prostaglandin-related compound are administered separately.

17. The method of claim 14 wherein said trefoil factor family peptide is administered in a dosage form comprising a mucoadhesive.

18. The method of claim 14 wherein said trefoil factor family peptide
10 comprises TFF1 or TFF3.

19. The method of claim 17 wherein said person is being treated with bimatoprost.

20. The method of claim 17 wherein said mucoadhesive comprises a polysaccharide.

15 21. The method of claim 19 wherein said trefoil factor family peptide is administered with Tamarind seed polysaccharide.

22. The dosage form of claim 1, wherein said prostaglandin or prostamide is a prostaglandin F-related compound.

23. The dosage form of claim 2 which comprises Tamarind seed
20 polysaccharide, about 0.5% sodium chloride, about 0.005% benzalkonium chloride, and about 0.6% of a borate buffer wherein the pH of the composition is adjusted to from about 6 to about 8.

24. The dosage form of claim 23 which comprises about 0.03% bimatoprost.

25. The dosage form of claim 23 which comprises about 0.005%
25 latanoprost.

26. The dosage form of claim 23 which comprises about 0.004% travoprost.

27. The dosage form of claim 23 which comprises about 0.15% unoprostone isopropyl.

28. A pharmaceutical product comprising

- a composition comprising a therapeutically effective amount of a prostaglandin F-related compound and a therapeutically effective concentration of a trefoil factor family peptide, and
a package suitable for ophthalmic use from which said composition is
5 dispensed,
wherein the use of the composition for the prevention or treatment of glaucoma is indicated thereon.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US2004/027777

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/17 A61K31/5575 A61P27/02
 //(A61K31/5575, 38:17)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 435 682 A (ALLERGAN INC) 3 July 1991 (1991-07-03) page 2, lines 47-51	1-28
A	US 2003/186886 A1 (PODOLSKY DANIEL K) 2 October 2003 (2003-10-02) paragraphs '0057! - '0060!; claims 1-11	1-28

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

30 November 2004

Date of mailing of the international search report

06/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3018

Authorized officer

Tardi, C

INTERNATIONAL SEARCH REPORT

national application No.
PCT/US2004/027777

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 14-21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/027777

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0435682	A	03-07-1991	AU 639284 B2	22-07-1993
			AU 6828390 A	04-07-1991
			CA 2031469 A1	29-06-1991
			EP 0435682 A2	03-07-1991
			IE 904711 A1	17-07-1991
			JP 6211666 A	02-08-1994
US 2003186886	A1	02-10-2003	US 2003134797 A1	17-07-2003
			US 6525018 B1	25-02-2003
			US 6221840 B1	24-04-2001
			US 2003185838 A1	02-10-2003
			US 2003186882 A1	02-10-2003
			US 2003185839 A1	02-10-2003
			US 2003181383 A1	25-09-2003
			US 2003181384 A1	25-09-2003
			AU 729564 B2	01-02-2001
			AU 2726897 A	07-11-1997
			BR 9710654 A	17-08-1999
			CA 2251631 A1	23-10-1997
			EP 0954330 A1	10-11-1999
			JP 2000508900 T	18-07-2000
			WO 9738712 A1	23-10-1997
			US 2003225250 A1	04-12-2003
			US 2002052483 A1	02-05-2002